Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Omeprazole vs Surgery for Peptic Esophagitis (10-Year Follow-up)
NCT00256737Phase 3Completed
- Sponsor
- AstraZeneca
- Start
- Jan 1998
- Primary completion
- Oct 2005
- Modality
- Small Molecules
- Countries
- 4
01
Overview
Phase 3, randomised, open-label trial of omeprazole in gastroesophageal reflux disease (GERD) (2 arms), sponsored by AstraZeneca. Primary endpoint: Safety of omeprazole during long term treatment at 10 years. Started Jan 1998; status: completed.
02
Drugs
omeprazole
03
Conditions
gastroesophageal reflux disease (GERD)
Beyond the preview
Go deeper on NCT00256737.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00256737.